Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development

PLoS One. 2017 Dec 7;12(12):e0189123. doi: 10.1371/journal.pone.0189123. eCollection 2017.

Abstract

CDKN2A coding region germline variants are associated with pancreatic adenocarcinoma (PC) susceptibility. Recently, we described functional germline 5'UTR CDKN2A variants from melanoma patients affecting the post-transcriptional regulation of p16INK4a mRNA that is dependent, at least in part, on an Internal Ribosome Entry Site (IRES) in the 5'UTR region. Here we describe a 5'UTR c.-201_-198delinsCTTT CDKN2A variant (frequency 0.0028 based on 350 PC patients), which seems to be private to PC, since it has never been found in public databases nor in thousands of melanoma patients tested. Functional analyses confirmed IRES activity of the 5'UTR in BX-PC3 PC cells and revealed a functional impact of the identified variant. Using gene reporter assays we observed reduced translation potential in cells treated with the mTOR inhibitor Torin1, a condition that favors the assessment of IRES activity. At the endogenous gene level we quantified allelic imbalance among polysome-associated mRNAs using a patient-derived cell line heterozygous for the c.-201_-198delinsCTTT. Overall, we conclude that this very rare private variant can be considered a potential mutation, specifically associated with PC. Our data indicate that sequencing of the entire 5'UTR of CDKN2A should be included in routine screening of PC cases with suspected inherited susceptibility.

MeSH terms

  • 5' Untranslated Regions*
  • Female
  • Germ-Line Mutation*
  • Humans
  • Male
  • Pancreatic Neoplasms / genetics*
  • Pedigree

Substances

  • 5' Untranslated Regions

Grants and funding

This work was supported by: IRCCS AOU San Martino-IST 5 per mille per la Ricerca Corrente to PG, Italian Association for Cancer Research AIRC IG15460 to PG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.